Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine +/- Cisplatin or Carboplatin in Adjuvant Intra-Hepatic Cholangiocarcinoma
NCT03081039Phase 3Withdrawn
- Sponsor
- University of Louisville
- Start
- Aug 2017
- Primary completion
- Apr 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin and carboplatin in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by University of Louisville. Primary endpoint: Overall Survival at 4 years. Planned start Aug 2017; status: withdrawn.
02
Drugs
cisplatincarboplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT03081039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03081039.